MedTrace Logo

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

NCT00981747 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-11-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether combination therapy with sildenafil and losartan can improve function and exercise tolerance in patients with idiopathic pulmonary fibrosis.

Conditions

Interventions

DRUG

Sildenafil

Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.

DRUG

Losartan

Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.

DRUG

Sildenafil and Losartan

Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.

DRUG

Placebo Oral Tablet

Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.

Sponsors & Collaborators

  • Pulmonary Fibrosis Foundation

    collaborator OTHER

  • Alicia Gerke

    lead OTHER

Principal Investigators

  • Alicia K Gerke, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2016-12-31
Completion
2016-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981747 on ClinicalTrials.gov